How Will The Generic Pharmaceuticals Contract Manufacturing Market Reach $87.59 Billion By 2029 Amid Global Shifts?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Current Size And Growth Outlook For The Generic Pharmaceuticals Contract Manufacturing Market?
The market size for generic pharmaceuticals contract manufacturing has significantly expanded in the past few years. Projected growth indicates an increase from $62.30 billion in 2024 to $66.82 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.3%. The historical growth can be associated with factors such as the growing demand for affordable medication, increased spending on healthcare in emerging economies, the expiration of patents for branded drugs, increased outsourcing activities by pharmaceutical firms, and the escalating prevalence of chronic illnesses.
Expectations are high for a robust expansion of the generic pharmaceuticals contract manufacturing market in the approaching years. The projections indicate an increase to $87.59 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. This upswing during the outlook period is credited to heightened attention on specialty generics, increased governmental backing of generic drug use, broadening healthcare reach in emergent markets, a surge in investment towards contract manufacturing facilities, and a rising demand for adaptable and scalable production solutions. The forecast period is set to be marked by significant trends such as advancements in manufacturing automation, sophisticated quality control techniques, the creation of intricate generic formulations, innovative drug delivery systems, and progress in continuous manufacturing processes.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
What Growth-Enabling Forces Are Impacting The Generic Pharmaceuticals Contract Manufacturing Market?
The surge in biosimilars popularity is predicted to fuel the expansion of the generic pharmaceuticals contract manufacturing market. Biosimilars, which are biological medical products highly akin to already authorized reference biologics, exhibit no significant variance in safety, purity, or effectiveness. The increasing interest in biosimilars is chiefly attributed to their capacity to offer cost-efficient counterparts to pricey biologic drugs, thereby making advanced therapies more achievable for patients and healthcare systems. Contract manufacturing in generic pharmaceuticals boosts biosimilars by offering cost-efficient mass production capacity and the required regulatory expertise to quicken market admission and maintain steady quality. As per Cardinal Health Inc., a healthcare organization located in the US, by January 2022, the US had granted approval to 33 biosimilar items, with 21 of them being available in the market. Moreover, by January 2023, the tally of FDA-authorized biosimilars had increased to 40, with 25 being commercially accessible by 2023. Consequently, the growing demand for biosimilars is propelling the expansion of the generic pharmaceuticals contract manufacturing market.
How Does The Generic Pharmaceuticals Contract Manufacturing Market Differ By Segment?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
What New Opportunities Are Emerging From Trends In The Generic Pharmaceuticals Contract Manufacturing Market?
Key players in the generic pharmaceutical contract manufacturing market are broadening their offerings through the creation of dedicated subsidiaries to adapt to the surging need for outsourced development and manufacturing. This strategy of setting up specific subsidiaries allows firms to simplify the production of active pharmaceutical ingredients (APIs), ensuring adherence to regulations, scalability, and operational effectiveness throughout the drug development process. For example, in July 2025, Lupin, a generic pharmaceutical enterprise based in India, initiated its new subsidiary, Lupin Manufacturing Solutions (LMS), marking its entry into the contract development and manufacturing organization (CDMO) market. This specialized branch is designed to aid in the development, production, and distribution of APIs for international pharmaceutical collaborators. With a management team proficient in biotech and pharma, the subsidiary is strategically placed to offer superior contract services, assisting pharmaceutical firms in accelerated market entry while ensuring regulatory compliance and cost optimization.
Who Are The Most Influential Companies In The Generic Pharmaceuticals Contract Manufacturing Market?
Major companies operating in the generic pharmaceuticals contract manufacturing market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Fresenius Kabi AG, WuXi AppTec Co. Ltd., Aurobindo Pharma, Cipla Limited, Recipharm AB, Siegfried Holding AG, Curia Global Inc., Torrent Pharmaceuticals Limited., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Pfizer CentreOne, Syngene International Ltd., Wockhardt Ltd., Alcami Corp. Inc, Neuland Laboratories Limited., Panacea Biotec Ltd., Jubilant Generics Ltd.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Generic Pharmaceuticals Contract Manufacturing Market?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25771&type=smp
Browse Through More Reports Similar to the Global Generic Pharmaceuticals Contract Manufacturing Market 2025, By The Business Research Company
Branded Generics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report
Pharmaceutical Continuous Manufacturing Global Market Report 2025
Fill Finish Pharmaceutical Contract Manufacturing Global Market Report 2025
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
